Traditional approaches to limit AT1R activation (AT1R antagonists, ACEi) have not convincingly slowed AAA progression in clinical studies, and novel pharmacological approaches like direct renin inhibitors, chymase inhibitors, and AT2R agonists have not yet been transferred from preclinical to clinical studies [2,41,42,43]. This evidence concerns the gene CMA1 and triple-A syndrome.